Free Trial
NASDAQ:ENLV

Enlivex Therapeutics (ENLV) Stock Price, News & Analysis

Enlivex Therapeutics logo
$1.13 -0.02 (-1.74%)
As of 01/17/2025 04:00 PM Eastern

About Enlivex Therapeutics Stock (NASDAQ:ENLV)

Key Stats

Today's Range
$1.12
$1.17
50-Day Range
$0.86
$1.30
52-Week Range
$0.81
$4.59
Volume
45,575 shs
Average Volume
87,022 shs
Market Capitalization
$24.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50
Consensus Rating
Buy

Company Overview

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
72nd Percentile Overall Score

ENLV MarketRank™: 

Enlivex Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 298th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enlivex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Enlivex Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Enlivex Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Enlivex Therapeutics are expected to grow in the coming year, from ($0.70) to ($0.58) per share.

  • Price to Book Value per Share Ratio

    Enlivex Therapeutics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Enlivex Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.58% of the outstanding shares of Enlivex Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Enlivex Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enlivex Therapeutics has recently decreased by 41.19%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enlivex Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Enlivex Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.58% of the outstanding shares of Enlivex Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Enlivex Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enlivex Therapeutics has recently decreased by 41.19%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Enlivex Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Enlivex Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for ENLV on MarketBeat in the last 30 days.
  • MarketBeat Follows

    6 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.02% of the stock of Enlivex Therapeutics is held by institutions.

  • Read more about Enlivex Therapeutics' insider trading history.
Receive ENLV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENLV Stock News Headlines

Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
Enlivex announces interim efficacy data from Phase I Allocetra trial
See More Headlines

ENLV Stock Analysis - Frequently Asked Questions

Enlivex Therapeutics' stock was trading at $1.17 at the beginning of 2025. Since then, ENLV stock has decreased by 3.4% and is now trading at $1.13.
View the best growth stocks for 2025 here
.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) issued its quarterly earnings results on Monday, June, 26th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40).

Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), CrowdStrike (CRWD), Adobe (ADBE) and Meta Platforms (META).

Company Calendar

Last Earnings
6/26/2023
Today
1/20/2025
Next Earnings (Estimated)
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENLV
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$13.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+740.7%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-29,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.62 per share

Miscellaneous

Free Float
18,777,000
Market Cap
$24.19 million
Optionable
Optionable
Beta
1.00
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:ENLV) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners